eFoodAlert.com (Free subscription) | 11/20/2009
Here is today's list of food safety recalls, product withdrawals and allergy alerts. The live links will take you directly to the official recall notices and company news releases that contain detailed information for each recall and alert. United States Allergy Alert: HP Hood, the manufacturer of Hannaford Eggnog , directs Hannaford Supermarkets to remove certain containers of the half-gallon size...
Public Offering blog (Free subscription) | 11/20/2009
Above: Healthcare conference team. As the vitriolic debate on healthcare reform dominates the news, healthcare industry leaders continue to focus on several issues: innovation to drive growth and promote cost efficiencies; new offerings to generate higher value for each healthcare dollar invested; and the emergence of attractive new global markets and technologies. They recognize that continued economic...
Contract Pharma Breaking News (Free subscription) | 11/20/2009
Ligand Pharmaceuticals, Inc. has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck , through its research collaboration, which is due to expire at the end of December. “We have had a long and productive drug discovery relationship with Organon and Schering-Plough (which acquired Organon in November 2007) over the years for a range of research programs,”...
market folly (Free subscription) | 11/19/2009
This is the third quarter 2009 edition of our hedge fund portfolio tracking series. If you're unfamiliar with tracking hedge fund movements or SEC filings, check out our series preface on hedge fund 13F filings . Next up in our series is Dan Loeb's Third Point LLC. Third Point is a multi-billion dollar hedge fund that has seen annual returns greater than 15% since inception. Manager Dan Loeb focuses...
San Fransisco Chronicle (Free subscription) | 11/19/2009
Ligand Pharmaceuticals Inc. said Thursday it received a $2 million milestone payment from Merck & Co. as part of a research collaboration. The company said the partnership covers a range of research programs. It is due to expire at the end of December. Ligand... Merck & Co - Business - Pharmaceutical - Biotechnology and Pharmaceuticals - Schering-Plough
Fiercebiotech (Free subscription) | 11/18/2009
Peter Thompson , Trubion Pharmaceuticals' president, CEO, chairman of the board and co-founder, has retired. Steven Gillis , former lead director of Trubion's board, has been appointed executive chairman of the board and acting president. Michelle Burris , Trubion's senior vice president and chief financial officer, will assume the role of chief operating officer, and John Bencich , the company's...
Pharmalot (Free subscription) | 11/18/2009
Now that Fred Hassan is no longer the chief executive of Schering-Plough - or any other drugmaker - since Merck finally scooped up its rival, Fred has been busy accepting invitations to join the boards of various other corporations. Apparently, his experience selling drugmakers - don’t forget his time running Pharmacia - is seen as [...]
Bio-IT World | Top Headlines (Free subscription) | 11/18/2009
Bio-IT World | SINGAPORE—“ If you Googled ‘biomarkers’ ten years ago, I think you’d end up with all kinds of websites on extraterrestrial life. Biomarkers: life in space!” jokes Erik Sprengers, site head of the Schering-Plough Translational Medicine Research Centre (TMRC).
SeekingAlpha ETFs (Free subscription) | 11/16/2009
ETF Database submits: Over the past few weeks, there has been a resurgence in acquisition activity, fueling an already strong market rally. This news has spanned all regions of the economy ranging from the transportation sector (Burlington Northern ( BNI ) being taken over by Berkshire Hathaway ( BRK.A )) to pharmaceuticals (Schering Plough ( SGP ) being acquired by Merck ( MRK )). Most recently,...
thepharmaletter.com (Free subscription) | 11/16/2009
USA-based Merck & Co, now the world’s number two drugmaker following its acquisition of Schering-Plough, says it remains confident about the safety and efficacy of its leading cholesterol-lowering drugs, despite the results of a much-anticipated head-to-head study which calls into question the level of effectiveness of Zetia (ezetimibe) and Vytorin. (ezetimibe and simvastatin).
SeekingAlpha ETFs (Free subscription) | 11/16/2009
Michael Johnston submits: Over the past few weeks, there has been a resurgence in acquisition activity, fueling an already strong market rally. This news has spanned all regions of the economy ranging from the transportation sector (Burlington Northern being taken over by Berkshire Hathaway) to pharmaceuticals (Schering Plough being acquired by Merck). Most recently, in the consumer sector, Kraft...
The Star-Ledger (Free subscription) | 11/16/2009
EPAMerck, strenghthened by its acquisition of Schering-Plough, becomes the No. 2 drug makerORLANDO, Fla. -- A study released Sunday raises fresh concerns about Zetia and its cousin, Vytorin — drugs still taken by millions of Americans to lower cholesterol, despite...
Madd Money (Free subscription) | 11/15/2009
Bullish Devon Energy Corp. (DVN), Apache Corp. (APA), ConAgra Foods Inc. (CAG), BP plc (NYSE:BP), Walgreens Company (NYSE:WAG) and Express Scripts Inc. (ESRX). Bearish Churchill Downs Inc. (CHDN), Chesapeake Energy Corporation (CHK), Tyson Foods Inc. (TSN) and CVS Caremark Corp. (CVS). Get the scoop on tomorrow’s hottest trade ideas – TODAY! [...]
The Earth Times Online Newspaper (Free subscription) | 11/14/2009
WHITEHOUSE STATION, N.J. - Following the completion of its merger with Schering-Plough, Merck today confirms and underscores its commitment to marketing and developing cardiovascular medicines for a range of cardiovascular disorders. Today's Merck has a robust portfolio and
Business Wire (Free subscription) | 11/14/2009
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Following the completion of its merger with Schering-Plough, Merck today confirms and underscores its commitment to marketing and developing cardiovascular medicines for a range of cardiovascular disorders. "Today's Merck has a robust portfolio and pipeline of cardiovascular medicines for conditions ranging from heart disease to metabolic syndrome. More...
The 3 latest articles published by users on Schering-Plough :
aarkstore | 09/04/2009
omprehensive Forecasts AND Detailed Budget Benchmarks "Oncology Roadmap," explores the fiercely competitive oncology market in a way that no other available forecast can match. Our experienced analysts have reviewed thousands of historical and forecasted data points to provide the most comprehensive oncology market outlook ever. At the same time, brand budget benchmarks reveal spending in key areas...
aarkstore | 08/13/2009
The animal health market is growing, albeit at a slower rate, in the recessionary economic phase. Two factors are working in favor of the industry – pet owners’ love for their companion animals and the economic reasons for the treatment of livestock or farm animals. The “livestock” segment, a high-volume market that represents around 57% of the international animal health market is guided mostly by...
pickpennystocks | 08/07/2009
TransDigm Group has purchased Acme Aerospace Business from Actuant Corporation for $40 million. TransDigm supplies aircraft companies with components and the addition of Acme Aerospace will accentuate TransDigm Group’s products. WPPS, a leading financial newsletter, is pleased to alert investors of stocks on the move. Sign...
Videos